Mortality in neurofibromatosis 1: an analysis using U.S. death certificates
- PMID: 11283797
- PMCID: PMC1226092
- DOI: 10.1086/320121
Mortality in neurofibromatosis 1: an analysis using U.S. death certificates
Abstract
Although neurofibromatosis 1 (NF1) is a relatively common autosomal dominant condition, information about its effect on mortality is limited. We used Multiple-Cause Mortality Files, compiled from U.S. death certificates by the National Center for Health Statistics, for 1983 through 1997. We identified 3,770 cases of presumed NF1 among 32,722,122 deaths in the United States, a frequency of 1/8,700, which is one-third to one-half the estimated prevalence. Mean and median ages at death for persons with NF1 were 54.4 and 59 years, respectively, compared with 70.1 and 74 years in the general population. Results of proportionate mortality ratio (PMR) analyses showed that persons with NF1 were 34 times more likely (PMR=34.3, 95% confidence interval [CI] 30.8-38.0) to have a malignant connective or other soft-tissue neoplasm listed on their death certificates than were persons without NF1. Overall, persons with NF1 were 1.2 times more likely than expected (PMR=1.21, 95% CI 1.14-1.28) to have a malignant neoplasm listed on their death certificates, but the PMR was 6.07 (95% CI 4.88-7.45) for persons who died at 10-19 years of age and was 4.93 (95% CI 4.14-5.82) for those who died at 20-29 years of age. Similarly, vascular disease was recorded more often than expected on death certificates of persons with NF1 who died at <30 years of age (PMR=3.26, 95% CI 1.31-6.71 at age <10 years; PMR=2.68, 95% CI 1.38-4.68 at age 10-19 years; and PMR=2.25, 95% CI 1.46-3.32 at 20-29 years) but not in older persons. This study supports previous findings of decreased life expectancy for persons with NF1 and, within the limitations of death certificates, provides population-based data about NF1 morbidity and mortality that are useful to clinicians caring for patients with NF1.
Figures
Similar articles
-
Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006).Orphanet J Rare Dis. 2011 Mar 25;6:11. doi: 10.1186/1750-1172-6-11. Orphanet J Rare Dis. 2011. PMID: 21439034 Free PMC article.
-
Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France.Orphanet J Rare Dis. 2011 May 4;6:18. doi: 10.1186/1750-1172-6-18. Orphanet J Rare Dis. 2011. PMID: 21542925 Free PMC article.
-
Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.Eur J Hum Genet. 2011 Nov;19(11):1187-91. doi: 10.1038/ejhg.2011.113. Epub 2011 Jun 22. Eur J Hum Genet. 2011. PMID: 21694737 Free PMC article.
-
Epidemiology of neurofibromatosis type 1.Am J Med Genet. 1999 Mar 26;89(1):1-6. Am J Med Genet. 1999. PMID: 10469430 Review.
-
Neurovascular complications in adults with Neurofibromatosis type 1: A national referral center experience.Am J Med Genet A. 2022 Oct;188(10):3009-3015. doi: 10.1002/ajmg.a.62931. Epub 2022 Aug 10. Am J Med Genet A. 2022. PMID: 36097643 Review.
Cited by
-
Selumetinib-A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis.Indian Dermatol Online J. 2024 Jun 26;15(4):701-705. doi: 10.4103/idoj.idoj_569_23. eCollection 2024 Jul-Aug. Indian Dermatol Online J. 2024. PMID: 39050082 Free PMC article. No abstract available.
-
Nf1 mutation disrupts activity-dependent oligodendroglial plasticity and motor learning in mice.Nat Neurosci. 2024 Aug;27(8):1555-1564. doi: 10.1038/s41593-024-01654-y. Epub 2024 May 30. Nat Neurosci. 2024. PMID: 38816530 Free PMC article.
-
[Neurofibromatosis type 1 associated with pheochromocytoma: a case report with a brief review of the literature].Probl Endokrinol (Mosk). 2023 Sep 11;70(2):53-64. doi: 10.14341/probl13345. Probl Endokrinol (Mosk). 2023. PMID: 38796761 Free PMC article. Review. Russian.
-
Multidisciplinary team for patients with neurocutaneous syndromes: The little discussed importance of dentistry.Clinics (Sao Paulo). 2024 Feb 15;79:100332. doi: 10.1016/j.clinsp.2024.100332. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 38364341 Free PMC article. Review.
-
Breast density in NF1 women: a retrospective study.Fam Cancer. 2024 Mar;23(1):35-40. doi: 10.1007/s10689-023-00355-y. Epub 2024 Jan 25. Fam Cancer. 2024. PMID: 38270845 Free PMC article.
References
Electronic-Database Information
-
- Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim (for NF1 [MIM 162200]) - PubMed
References
-
- Ahlbom A (1993) Biostatistics for epidemiologists. Lewis, Boca Raton, FL
-
- Airewele GE, Sigurdson AJ, Wiley KJ, Frieden BE, Caldarera LW, Riccardi VM, Lewis RA, Chintagumpala MM, Ater JL, Plon SE, Bondy ML (2001) Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol 20:75–86 - PubMed
-
- Decoufle P, Thomas TL, Pickle LW (1980) Comparison of the proportionate mortality ratio and standardized mortality ratio risk measures. Am J Epidemiol 111:263–269 - PubMed
-
- Fossali E, Signorini E, Intermite RC, Casalini E, Lovaria A, Maninetti MM, Rossi LN (2000) Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 14:806–810 - PubMed
-
- Hattori S, Kiguchi H, Ishii T, Nakajima T, Yatsuzuka H (1998) Moyamoya disease with concurrent von Recklinghausen's disease and cerebral arteriovenous malformation. Pathol Res Pract 194:363–369 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous